bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Authors: Ibrahim Ahmed Atef , Schmithals Christian , Kowarz Erik , Köberle Verena , Kakoschky Bianca , Pleli Thomas , Kollmar Otto , Nitsch Scarlett , Waidmann Oliver , Finkelmeier Fabian , Zeuzem Stefan , Korf Horst-Werner , Schmid Tobias , Weigert Andreas , Kronenberger Bernd , Marschalek Rolf , Piiper Albrecht
Published: April 2023

Supplementary Fig. S3. Doxycyline-induced overexpression of Dicer in HCC cells. HepG2 (A) and Huh-7 (B) cells stably transfected with the inducible Dicer construct were incubated with or without doxycycline (Dox) for 24 h. C: HepG2 cells with the inducible Dicer construct were incubated for the indicated duration with or without doxycycline. A-C: The lysates were analyzed by immunoblotting using anti-Dicer and anti-β-actin antibodies. D: Western blot analysis of Dicer protein expression in Dicer-transgenic HepG2 xenografts from mice treated for 7 days with doxycycline (n = 3) or vehicle (n = 4), that were used for the experiment displayed in Fig. 5F. A-D: β-actin was used as endogenous control.
Figure S2 from Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Authors: Zhang Jia-Xing , Chen Zhen-Hua , Xu Yi , Chen Jie-Wei , Weng Hui-Wen , Yun Miao , Zheng Zou-San , Chen Cui , Wu Bing-Li , Li En-Min , Fu Jian-Hua , Ye Sheng , Xie Dan
Published: April 2023

Figure S2. PITX2 is a direct target of miR-644a in ESCC. A, miR-644a and its putative binding sequence in the 3'-UTR of PITX2. The mutant miR-644a-binding site was generated in the complementary site for the seed region of miR-644a (wt: wild type; mt: mutant type). B, miR-644a significantly suppressed the luciferase activity that carried wt but not mt 3'-UTR of PITX2. C and D, up-regulation of miR-644a significantly reduced PITX2 protein (C) and mRNA levels (D) of KYSE-140 and Eca-109 cells. E, PITX2 expression in subcutaneous implantation models of KYSE-140 and Eca-109 cells detected by IHC staining. **P<0.01. *P<0.05.
Supplemental Figure S1 from High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial
Authors: Nielsen Torsten O. , Jensen Maj-Brit , Burugu Samantha , Gao Dongxia , Jørgensen Charlotte L. Tykjaer , Balslev Eva , Ejlertsen Bent
Published: April 2023

Overall Survival analyses. A: Kaplan-Meier estimates of the DBCG77B TMA-IHC intrinsic subtype dataset, stratified by chemotherapy (CT) and Luminal A status, out to 25-yr follow-up. B: Forest plot, stratified by time since randomization due to non-proportionality of the hazard ratio for treatment effect across the full follow-up period.
Figure S1 from Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Authors: Zhang Jia-Xing , Chen Zhen-Hua , Xu Yi , Chen Jie-Wei , Weng Hui-Wen , Yun Miao , Zheng Zou-San , Chen Cui , Wu Bing-Li , Li En-Min , Fu Jian-Hua , Ye Sheng , Xie Dan
Published: April 2023

The effect of miR-644a on cell growth, migration and invasion of KYSE-410 cell line in vitro. A and B, down-regulation of miR-644a significantly promoted cell growth (A) and colony formation (B) compared with that of control cells. C, the wound healing rate in anti-miR-644a-transfected cells was significantly increased. D, the number of invaded cell in anti-miR-644a-transfected group was significantly increased compared to the control group. **P<0.01, *P<0.05.
Supplementary Tables 6-9 from Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Authors: Parkhurst Maria , Gros Alena , Pasetto Anna , Prickett Todd , Crystal Jessica S. , Robbins Paul , Rosenberg Steven A.
Published: April 2023

These tables contain data representing the screening of TIL for recognition of mutated tandem mini-gene constructs.
Supplementary Figures from Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Authors: Parkhurst Maria , Gros Alena , Pasetto Anna , Prickett Todd , Crystal Jessica S. , Robbins Paul , Rosenberg Steven A.
Published: April 2023

These figures present data describing the recognition of neoantigens by T cells and TCRs not presented in the main body of the text.
Figure S6 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
Authors: Depreeuw Jeroen , Stelloo Ellen , Osse Elisabeth M. , Creutzberg Carien L. , Nout Remi A. , Moisse Matthieu , Garcia-Dios Diego A. , Dewaele Michael , Willekens Karen , Marine Jean-Christophe , Matias-Guiu Xavier , Amant Frédéric , Lambrechts Diether , Bosse Tjalling
Published: April 2023

TP53 protein expression in NSMP ECs (1q32.1 normal and 1q32.1 amplified) and TP53-mutant ECs from the TCGA dataset with RPPA data available (n=126).
Figure S5 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
Authors: Depreeuw Jeroen , Stelloo Ellen , Osse Elisabeth M. , Creutzberg Carien L. , Nout Remi A. , Moisse Matthieu , Garcia-Dios Diego A. , Dewaele Michael , Willekens Karen , Marine Jean-Christophe , Matias-Guiu Xavier , Amant Frédéric , Lambrechts Diether , Bosse Tjalling
Published: April 2023

PSI index to associate 1q32.1 amplification with MDM4fl protein expression in NSMP ECs from the TCGA dataset with RNASeq data available (n=90).
Supplementary Table 2 from Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Tarlock Katherine , Alonzo Todd A. , Loken Michael R. , Gerbing Robert B. , Ries Rhonda E. , Aplenc Richard , Sung Lillian , Raimondi Susana C. , Hirsch Betsy A. , Kahwash Samir B. , McKenney Amy , Kolb E. Anders , Gamis Alan S. , Meshinchi Soheil
Published: April 2023

Supplementary Table 2. Multivariable cox analyses for outcomes adjusted for risk groups according to CD135 expression.
Figure S2 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
Authors: Depreeuw Jeroen , Stelloo Ellen , Osse Elisabeth M. , Creutzberg Carien L. , Nout Remi A. , Moisse Matthieu , Garcia-Dios Diego A. , Dewaele Michael , Willekens Karen , Marine Jean-Christophe , Matias-Guiu Xavier , Amant Frédéric , Lambrechts Diether , Bosse Tjalling
Published: April 2023

Significantly amplified and deleted regions (focal and whole-arm) of the SCNA clusters.
Supplemental material and method from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Authors: Ogitani Yusuke , Aida Tetsuo , Hagihara Katsunobu , Yamaguchi Junko , Ishii Chiaki , Harada Naoya , Soma Masako , Okamoto Hiromi , Oitate Masataka , Arakawa Shingo , Hirai Takehiro , Atsumi Ryo , Nakada Takashi , Hayakawa Ichiro , Abe Yuki , Agatsuma Toshinori
Published: April 2023

Cell line and patient-derived xenograft studies
Supplementary Table 3. Serum levels of cytokines by flow cytometry. from Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial
Authors: Caballero-Velázquez Teresa , Montero Isabel , Sánchez-Guijo Fermín , Parody Rocío , Saldaña Raquel , Valcarcel David , López-Godino Oriana , Ferra i Coll Christelle , Cuesta Marian , Carrillo-Vico Antonio , Sánchez-Abarca Luis I. , López-Corral Lucía , Márquez-Malaver Francisco J. , Pérez-Simón José A.
Published: April 2023

Serum levels of cytokines by flow cytometry. Serum levels of Th1/Th2 cytokines are summarized in this table.
Supplementary Figure A1 online only. from Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial
Authors: Caballero-Velázquez Teresa , Montero Isabel , Sánchez-Guijo Fermín , Parody Rocío , Saldaña Raquel , Valcarcel David , López-Godino Oriana , Ferra i Coll Christelle , Cuesta Marian , Carrillo-Vico Antonio , Sánchez-Abarca Luis I. , López-Corral Lucía , Márquez-Malaver Francisco J. , Pérez-Simón José A.
Published: April 2023

Cumulative incidence of relapse (A) or NRM (B): No significant differences between the different cohorts of patients were observed in terms of cumulative incidence of relapse or NRM (p=0.1 and p= 0.8).
Supplementary Figure 1 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Vigneri Paolo , Stagno Fabio , Stella Stefania , Cupri Alessandra , Forte Stefano , Massimino Michele , Antolino Agostino , Siragusa Sergio , Mannina Donato , Impera Stefana Stella , Musolino Caterina , Malato Alessandra , Mineo Giuseppe , Tomaselli Carmela , Murgano Pamela , Musso Maurizio , Morabito Fortunato , Molica Stefano , Martino Bruno , Manzella Livia , Müller Martin C. , Hochhaus Andreas , Raimondo Francesco Di
Published: April 2023

Figure 1. Eight-year estimates, in an intention-to-treat analysis, for OS (solid line) and TFS (dashed line) in 272 CML patients receiving IM 400 mg/daily as first line therapy. At 60 months, OS was 93%, while TFS was 97.5%. Vertical lines indicate censored patients.
Supplementary Tables S1-S4 from Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis
Authors: Pichler Martin , Stiegelbauer Verena , Vychytilova-Faltejskova Petra , Ivan Cristina , Ling Hui , Winter Elke , Zhang Xinna , Goblirsch Matthew , Wulf-Goldenberg Annika , Ohtsuka Masahisa , Haybaeck Johannes , Svoboda Marek , Okugawa Yoshinaga , Gerger Armin , Hoefler Gerald , Goel Ajay , Slaby Ondrej , Calin George Adrian
Published: April 2023

Lists 4 Tables for Supplementary Information
Table S4 from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

Liver enzymes measured in NKG2D-CAR treated and control mice.
Figure S1 from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

531MII YFP-luc cells are only found in the lungs of those mice untreated (control) or treated with untransduced memory T cells.
Supplementary Table S5 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S5: Comparison of the mutational frequencies between metaplastic breast cancers with different morphologic features. Genes recurrently mutated in any of the groups in each comparison are included.
Supplementary Table S4 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S4: Significantly mutated genes analysis of metaplastic breast cancers (n=35) using MutSigCV and the algorithm proposed by Youn and Simon.
Supplementary Table S3 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S3: Comparison of the mutational frequencies in metaplastic breast cancers, metaplastic breast cancers of triple-negative phenotype and triple-negative invasive ductal carcinomas of no special type. Genes with non-synonymous mutations in >5% of samples from either group of each comparison are included.
Supplementary table and figure legends from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Supplementary table and figure legends
Supplementary Figure S4 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Fig. S4. Mutational signatures and genetic alterations affecting genes in the homologous recombination DNA repair pathway in metaplastic breast cancers (MBCs) and triple-negative invasive carcinomas of no special type (IDC-NSTs). (a) In bar graphs illustrating the mutational signatures, the mutations were grouped by the sequence context (i.e. AxA, AxC, AxG, AxT, CxA, CxC, CxG... TxT, where x is the mutated base), with the different colors indicating the mutation type (i.e. C>A, C>G, C>T, T>A, T>C and T>G). The height of colored bars represents the fraction of mutations attributed in each of the 96 sub-bins. (b) Genetic alterations that would result in the bi-allelic inactivation (i.e. two mutations in the same gene, one mutation associated with loss of heterozygosity or homozygous deletion) of genes known to be involved in homologous recombination DNA repair (see Supplementary Table S6) are color-coded by their effect according to the legend. Genes mutated in at least one MBC or triple-negative IDC-NST are included and are ordered from top to bottom in decreasing order of mutational frequency in MBCs. The presence of loss of heterozygosity of the wild-type allele of a mutated gene is represented by a diagonal bar. Percentages to the right indicate the percentage of cases affected by non-synonymous somatic mutations in a given gene. TCGA, The Cancer Genome Atlas.
Supplementary Table 10 from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Selected key pathways up-regulated or down-regulated by ACEi treatment alone in Gene Set Enrichment Analysis.
Supplementary methods and figure legends from Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Authors: Niemann Carsten U. , Mora-Jensen Helena I. , Dadashian Eman L. , Krantz Fanny , Covey Todd , Chen Shih-Shih , Chiorazzi Nicholas , Izumi Raquel , Ulrich Roger , Lannutti Brian J. , Wiestner Adrian , Herman Sarah E.M.
Published: April 2023

Supplementary methods and figure legends
Suppl. Figure 6 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

Restoration of REDD1 expression counteracts miR-22-mediated Taxol sensitivity. EJ and BIU87 cells were treated with Taxol and combinations of miR-22 mimics, miR-22 antagonist, shRNA-REDD1, and REDD1 overexpression vector. (A) Protein expression of REDD1, EEF2K, c-caspase 3, c-PARP, and LC3-I/II was determined by western blot. (B) CCK-8 was used to determine treatment effect on cell proliferation. (C) Flow cytometry was used to detect cell apoptosis. (D) Autophagy was assessed by immunofluorescence of LCB3 and quantification by flow cytometry. ***P<0.001, **P<0.01, *P<0.05.
Supplementary Movie S1 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Authors: Jiao Shiping , Xia Weiya , Yamaguchi Hirohito , Wei Yongkun , Chen Mei-Kuang , Hsu Jung-Mao , Hsu Jennifer L. , Yu Wen-Hsuan , Du Yi , Lee Heng-Huan , Li Chia-Wei , Chou Chao-Kai , Lim Seung-Oe , Chang Shih-Shin , Litton Jennifer , Arun Banu , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PARPi treatment inhibits cell proliferation of MDA-MB-231 cells. Time-lapse video of 231 (Nuc-RFP) cells without olaparib (control) taken using the IncuCyte Zoom microscope.
Supplemental Table 3 from CD103 and Intratumoral Immune Response in Breast Cancer
Authors: Wang Zhi-Qiang , Milne Katy , Derocher Heather , Webb John R. , Nelson Brad H. , Watson Peter H.
Published: April 2023

Supplemental Table 3. CD103 positive TIL and association with clinical-pathological features.
Figure S2 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary Figure
Supplemental Table 1 from Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act
Authors: Kehl Kenneth L. , Fullmer Cheryl P. , Fu Siqing , George Goldy C. , Hess Kenneth R. , Janku Filip , Karp Daniel D. , Kato Shumei , Kizer Cynthia K. , Kurzrock Razelle , Naing Aung , Pant Shubham , Piha-Paul Sarina A. , Subbiah Vivek , Tsimberidou Apostolia M. , Hong David S.
Published: April 2023

Sensitivity analysis: Only first referral for each patient included
Supplemental Figure 1 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma
Authors: Amin Jay , Xu Bo , Badkhshan Shervin , Creighton Terrance T. , Abbotoy Daniel , Murekeyisoni Christine , Attwood Kristopher M. , Schwaab Thomas , Hendler Craig , Petroziello Michael , Roche Charles L. , Kauffman Eric C.
Published: April 2023

Non-PEER CT peak signal intensity/enhancement values in RO versus ChRCC tumors according to CD117 expression. (A) Net peak enhancement using the delayed/excretory contrast phase relative to the unenhanced phase; (B) Absolute peak signal intensity using an early (arterial/cortical or venous/nephrogenic) contrast phase without subtraction of the unenhanced phase signal intensity; (C) Absolute peak signal intensity using the delayed/excretory contrast phase without subtraction of the unenhanced phase signal intensity.
Figure S6 from Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy
Authors: Ott Martina , Kassab Cynthia , Marisetty Anantha , Hashimoto Yuuri , Wei Jun , Zamler Daniel , Leu Jia-Shiun , Tomaszowski Karl-Heinz , Sabbagh Aria , Fang Dexing , Gupta Pravesh , Priebe Waldemar , Zielinski Rafal J. , Burks Jared K. , Long James P. , Kong Ling-Yuan , Fuller Gregory N. , DeGroot John , Sulman Erik P. , Heimberger Amy B.
Published: April 2023

Figure S6 shows heat maps from brain immune cells based on their function
Supplementary Table S1 from Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Authors: Harrington Kevin J. , Kong Anthony , Mach Nicolas , Chesney Jason A. , Fernandez Beatriz Castelo , Rischin Danny , Cohen Ezra E.W. , Radcliffe Hoi-Shen , Gumuscu Burak , Cheng Jonathan , Snyder Wendy , Siu Lillian L.
Published: April 2023

Confirmed best overall response per irRECIST by baseline PD-L1 CPS of {greater than or equal to} 1, {greater than or equal to} 20, and {greater than or equal to} 50
Supplementary Table 4 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
Authors: LeBlanc Amy K. , Mazcko Christina N. , Cherukuri Aswini , Berger Erika P. , Kisseberth William C. , Brown Megan E. , Lana Susan E. , Weishaar Kristen , Flesner Brian K. , Bryan Jeffrey N. , Vail David M. , Burton Jenna H. , Willcox Jennifer L. , Mutsaers Anthony J. , Woods J. Paul , Northrup Nicole C. , Saba Corey , Curran Kaitlin M. , Leeper Haley , Wilson-Robles Heather , Wustefeld-Janssens Brandan G. , Lindley Stephanie , Smith Annette N. , Dervisis Nikolaos , Klahn Shawna , Higginbotham Mary Lynn , Wouda Raelene M. , Krick Erika , Mahoney Jennifer A. , London Cheryl A. , Barber Lisa G. , Balkman Cheryl E. , McCleary-Wheeler Angela L. , Suter Steven E. , Martin Olya , Borgatti Antonella , Burgess Kristine , Childress Michael O. , Fidel Janean L. , Allstadt Sara D. , Gustafson Daniel L. , Selmic Laura E. , Khanna Chand , Fan Timothy M.
Published: April 2023

Supplementary Table 4 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC + sirolimus clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.
Supplementary Table 3 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
Authors: LeBlanc Amy K. , Mazcko Christina N. , Cherukuri Aswini , Berger Erika P. , Kisseberth William C. , Brown Megan E. , Lana Susan E. , Weishaar Kristen , Flesner Brian K. , Bryan Jeffrey N. , Vail David M. , Burton Jenna H. , Willcox Jennifer L. , Mutsaers Anthony J. , Woods J. Paul , Northrup Nicole C. , Saba Corey , Curran Kaitlin M. , Leeper Haley , Wilson-Robles Heather , Wustefeld-Janssens Brandan G. , Lindley Stephanie , Smith Annette N. , Dervisis Nikolaos , Klahn Shawna , Higginbotham Mary Lynn , Wouda Raelene M. , Krick Erika , Mahoney Jennifer A. , London Cheryl A. , Barber Lisa G. , Balkman Cheryl E. , McCleary-Wheeler Angela L. , Suter Steven E. , Martin Olya , Borgatti Antonella , Burgess Kristine , Childress Michael O. , Fidel Janean L. , Allstadt Sara D. , Gustafson Daniel L. , Selmic Laura E. , Khanna Chand , Fan Timothy M.
Published: April 2023

Supplementary Table 3 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.
Supplementary Data from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor
Authors: Ogura Koichi , Somwar Romel , Hmeljak Julija , Magnan Heather , Benayed Ryma , Momeni Boroujeni Amir , Bowman Anita S. , Mattar Marissa S. , Khodos Inna , de Stanchina Elisa , Jungbluth Achim , Asher Marina , Odintsov Igor , Hartono Alifiani B. , LaQuaglia Michael P. , Slotkin Emily , Pratilas Christine A. , Lee Sean Bong , Spraggon Lee , Ladanyi Marc
Published: April 2023

Supplementary Table 1
Table S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Authors: Gopal Ajay K. , Levy Ronald , Houot Roch , Patel Sandip P. , Popplewell Leslie , Jacobson Caron , Mu Xinmeng J. , Deng Shibing , Ching Keith A. , Chen Ying , Davis Craig B. , Huang Bo , Fly Kolette D. , Thall Aron , Woolfson Adrian , Bartlett Nancy L.
Published: April 2023

Pharmacokinetic parameters for utomilumab in combination with rituximab (Cycle 1)
Supplementary Figure S3 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Authors: Gopal Ajay K. , Levy Ronald , Houot Roch , Patel Sandip P. , Popplewell Leslie , Jacobson Caron , Mu Xinmeng J. , Deng Shibing , Ching Keith A. , Chen Ying , Davis Craig B. , Huang Bo , Fly Kolette D. , Thall Aron , Woolfson Adrian , Bartlett Nancy L.
Published: April 2023

Gene signatures in baseline peripheral blood samples associated with prognosis in follicular lymphoma patients treated with rituximab and utomilumab. Higher, normalized enrichment scores (NES) correspond to poorer survival. NES were derived from gene set enrichment analysis with genes pre-ranked by hazard ratio from multivariate Cox proportional-hazards model stratified by dose levels and adjusting for age, sex, race, stage, and whether patients had progressed on prior rituximab-containing therapy. Gene sets assessed were derived from the Molecular Signatures Database (MSigDB) hallmark collection (Liberzon et al, Cell Syst 2015;1:417-25). Only significant cell populations are shown (FDR-adjusted q value <0.05).
Supplementary Figure S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Authors: Gopal Ajay K. , Levy Ronald , Houot Roch , Patel Sandip P. , Popplewell Leslie , Jacobson Caron , Mu Xinmeng J. , Deng Shibing , Ching Keith A. , Chen Ying , Davis Craig B. , Huang Bo , Fly Kolette D. , Thall Aron , Woolfson Adrian , Bartlett Nancy L.
Published: April 2023

(A) Levels of soluble 4-1BB/CD137 and (B) changes in CD8+ T cells from Cycle 1 day 1, in individual patients by dose group.
Figure S4 from A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
Authors: Kazmi Farasat , Nicum Shibani , Roux Rene L. , Spiers Laura , Gnanaranjan Chat , Sukumaran Ajithkumar , Gabra Hani , Ghazaly Essam , McCracken Nigel W. , Harrison David J. , Blagden Sarah P.
Published: April 2023

Fit of population PK model to observed plasma concentrations
Supplementary Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Authors: Hellmann Matthew D. , Nabet Barzin Y. , Rizvi Hira , Chaudhuri Aadel A. , Wells Daniel K. , Dunphy Mark P.S. , Chabon Jacob J. , Liu Chih Long , Hui Angela B. , Arbour Kathryn C. , Luo Jia , Preeshagul Isabel R. , Moding Everett J. , Almanza Diego , Bonilla Rene F. , Sauter Jennifer L. , Choi Hyejin , Tenet Megan , Abu-Akeel Mohsen , Plodkowski Andrew J. , Perez Johnston Rocio , Yoo Christopher H. , Ko Ryan B. , Stehr Henning , Gojenola Linda , Wakelee Heather A. , Padda Sukhmani K. , Neal Joel W. , Chaft Jamie E. , Kris Mark G. , Rudin Charles M. , Merghoub Taha , Li Bob T. , Alizadeh Ash A. , Diehn Maximilian
Published: April 2023

Supplementary Data Legends.
Supplementary Data from Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity
Authors: Hong Bangxing , Chapa Valerie , Saini Uksha , Modgil Puneet , Cohn David E. , He Guangan , Siddik Zahid H. , Sood Anil K. , Yan Yuanqing , Selvendiran Karuppaiyah , Pei Guangsheng , Zhao Zhongming , Yoo Ji Young , Kaur Balveen
Published: April 2023

Supplementary Data
Supplementary Figure S4 from Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Authors: Hollebecque Antoine , Salvagni Stefania , Plummer Ruth , Isambert Nicolas , Niccoli Patricia , Capdevila Jaume , Curigliano Giuseppe , Moreno Victor , Martin-Romano Patricia , Baudin Eric , Arias Marina , Mora Sheila , de Alvaro Juan , Di Martino Jorge , Parra-Palau Josep L. , Sánchez-Pérez Tania , Aronchik Ida , Filvaroff Ellen H. , Lamba Manisha , Nikolova Zariana , de Bono Johann S.
Published: April 2023

Supplementary Figure S4. Dose-Normalized CC-90011 Parameters by Dose Level. Box plots of dose-normalized AUC0-168 (A) and Cmax (B) after day 1 dosing. Boxes represent the interquartile range, white horizontal lines indicate the median, and open circles represent individual values. AUC0-168, area under the plasma concentration-time curve from time 0 to 168 hours; Cmax, maximum plasma drug concentration. Data cutoff: 3 May 2019.
Supplementary Figure S3 from Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Authors: Hollebecque Antoine , Salvagni Stefania , Plummer Ruth , Isambert Nicolas , Niccoli Patricia , Capdevila Jaume , Curigliano Giuseppe , Moreno Victor , Martin-Romano Patricia , Baudin Eric , Arias Marina , Mora Sheila , de Alvaro Juan , Di Martino Jorge , Parra-Palau Josep L. , Sánchez-Pérez Tania , Aronchik Ida , Filvaroff Ellen H. , Lamba Manisha , Nikolova Zariana , de Bono Johann S.
Published: April 2023

Supplementary Figure S3. Platelet Count Over Time in Response to CC-90011 at the RP2D (A), MTD (B), and NTD (C). Error bars indicate range. C, cycle; D, day; MTD, maximum tolerated dose; NTD, nontolerated dose; RP2D, recommended phase 2 dose. Data cutoff: 3 May 2019.
Supplementary Figure Legend from Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Authors: Schoenfeld Adam J. , Chan Joseph M. , Kubota Daisuke , Sato Hiroki , Rizvi Hira , Daneshbod Yahya , Chang Jason C. , Paik Paul K. , Offin Michael , Arcila Maria E. , Davare Monika A. , Shinde Ujwal , Pe'er Dana , Rekhtman Natasha , Kris Mark G. , Somwar Romel , Riely Gregory J. , Ladanyi Marc , Yu Helena A.
Published: April 2023

Supplementary Figure Legend
Supplementary Table 1 from Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Authors: Dhani Neesha C. , Hirte Hal W. , Wang Lisa , Burnier Julia V. , Jain Angela , Butler Marcus O. , Welch Stephen , Fleming Gini F. , Hurteau Jean , Matsuo Koji , Matei Daniela , Jimenez Waldo , Johnston Carolyn , Cristea Mihaela , Tonkin Katia , Ghatage Prafull , Lheureux Stephanie , Mehta Anjali , Quintos Judy , Tan Qian , Kamel-Reid Suzanne , Ludkovski Olga , Tsao Ming-Sound , Wright John J. , Oza Amit M.
Published: April 2023

Supplemental Table S1. 48 genes included in the TruSeq Amplicon Cancer Panel (TSACP, Illumina). Panel includes 212 amplicons covering a total genomic region 35.84 kb.
Supplementary Data from Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
Authors: Isomoto Kohsuke , Haratani Koji , Hayashi Hidetoshi , Shimizu Shigeki , Tomida Shuta , Niwa Takashi , Yokoyama Toshihide , Fukuda Yasushi , Chiba Yasutaka , Kato Ryoji , Tanizaki Junko , Tanaka Kaoru , Takeda Masayuki , Ogura Takashi , Ishida Tadashi , Ito Akihiko , Nakagawa Kazuhiko
Published: April 2023

Supplementary_Figurelegends
Supplementary Table S1 from Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Authors: Kiyokawa Juri , Kawamura Yoichiro , Ghouse Shanawaz M. , Acar Simge , Barçın Erinç , Martínez-Quintanilla Jordi , Martuza Robert L. , Alemany Ramon , Rabkin Samuel D. , Shah Khalid , Wakimoto Hiroaki
Published: April 2023

Supplementary Table S1
Supplementary Materials from ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma
Authors: Myojin Yuta , Kodama Takahiro , Maesaka Kazuki , Motooka Daisuke , Sato Yu , Tanaka Satoshi , Abe Yuichi , Ohkawa Kazuyoshi , Mita Eiji , Hayashi Yoshito , Hikita Hayato , Sakamori Ryotaro , Tatsumi Tomohide , Taguchi Ayumu , Eguchi Hidetoshi , Takehara Tetsuo
Published: April 2023

Supplementary materials and supplementary figure legends 1-5.
Supplementary Data from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Authors: Li Yingming , Yang Rendong , Henzler Christine M. , Ho Yeung , Passow Courtney , Auch Benjamin , Carreira Suzanne , Nava Rodrigues Daniel , Bertan Claudia , Hwang Tae Hyun , Quigley David A. , Dang Ha X. , Morrissey Colm , Fraser Michael , Plymate Stephen R. , Maher Christopher A. , Feng Felix Y. , de Bono Johann S. , Dehm Scott M.
Published: April 2023

Supplementary Materials and Methods, Supplementary References, Supplementary Figures 1-8, Supplementary Tables 1-6
Supplementary Data 3 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Authors: Li Yingming , Yang Rendong , Henzler Christine M. , Ho Yeung , Passow Courtney , Auch Benjamin , Carreira Suzanne , Nava Rodrigues Daniel , Bertan Claudia , Hwang Tae Hyun , Quigley David A. , Dang Ha X. , Morrissey Colm , Fraser Michael , Plymate Stephen R. , Maher Christopher A. , Feng Felix Y. , de Bono Johann S. , Dehm Scott M.
Published: April 2023

AR Gene Alterations in WGS Cohort
Supplementary Materials and Methods from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Authors: Louveau Baptiste , Resche-Rigon Matthieu , Lesimple Thierry , Da Meda Laetitia , Pracht Marc , Baroudjian Barouyr , Delyon Julie , Amini-Adle Mona , Dutriaux Caroline , Reger de Moura Coralie , Sadoux Aurélie , Jouenne Fanélie , Ghrieb Zineb , Vilquin Paul , Bouton Didier , Tibi Annick , Huguet Samuel , Rezai Keyvan , Battistella Maxime , Mourah Samia , Lebbe Céleste
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure 8 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

Supplementary Figure
Supplementary Figure S1 from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Authors: Hunter Anthony M. , Newman Hannah , Dezern Amy E. , Steensma David P. , Niyongere Sandrine , Roboz Gail J. , Mo Qianxing , Chan Onyee , Gerds Aaron , Sallman David A. , Dominguez-Viqueira William , Letson Christopher , Balasis Maria E. , Ball Markus , Kruer Traci , Zhang Hailing , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S. , Padron Eric
Published: April 2023

Supplementary Figure S1 depicts the study schema.
Supplementary Material and Methods from CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors
Authors: Labiano Sara , Roh Vincent , Godfroid Céline , Hiou-Feige Agnès , Romero Jackeline , Sum Eva , Rapp Moritz , Boivin Gael , Wyss Tania , Simon Christian , Bourhis Jean , Umaña Pablo , Trumpfheller Christine , Tolstonog Genrich V. , Vozenin Marie-Catherine , Romero Pedro
Published: April 2023

Supplementary material and methods
Supp FIgure 8 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure
Figure S4 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Authors: Si Han , Kuziora Michael , Quinn Katie J. , Helman Elena , Ye Jiabu , Liu Feng , Scheuring Urban , Peters Solange , Rizvi Naiyer A. , Brohawn Philip Z. , Ranade Koustubh , Higgs Brandon W. , Banks Kimberly C. , Chand Vikram K. , Raja Rajiv
Published: April 2023

GuardantOMNI assay success rates
Supp FIgure 1 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure 1
Supplementary Figure S4 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

Association between NECTIN4 mRNA expression and clinical characteristics in the Seiler cohort for (A) sex (p<0.001), (B) age (p=0.11), (C) clinical stage (p=0.18), and (D) pathological stage (p=0.053). The p value from Kruskal-Wallis testing is shown for each panel.
Supplementary Figure S3 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

(A) IHC for NECTIN4 protein in a bladder cancer tissue microarray (TMA) shows heterogeneous staining patterns. Three representative tumors are depicted. NECTIN4 protein is localized primarily to the cell surface in tumors that were positive. The TMA was prepared using samples taken before neoadjuvant chemotherapy, at the time of TURBT (transurethral resection of the bladder tumor), as previously described in Ref [15] (B) H-scores for the TMA (n=80 samples, in duplicate) were independently assigned in a blinded manner by two pathologists. The average H-score for NECTIN4 for each sample was determined and plotted for each molecular subtype. There were no neuroendocrine bladder cancer samples in the TMA.
Supplementary Figure S2 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

Gene expression analysis of NECTIN4 correlates. (A) Correlation between NECTIN4 and GATA3 mRNA expression across the Seiler 2017 (left), Sjödahl 2012 (middle), and TCGA (right) cohorts. (B) Correlation between NECTIN4 and FOXA1 mRNA expression across Seiler 2017 (left), Sjödahl 2012 (middle), and TCGA (right) cohorts. (C) Correlation between NECTIN4 and PPARG mRNA expression across Seiler 2017 (left), Sjödahl 2012 (middle), and TCGA (right) cohorts. (D) Centroid values from the consensus molecular classifier by Kamoun et al. for NECTIN4, FOXA1, GATA3, and PPARG. (E) Kaplan-Meier curves of overall survival stratified by quartiles of NECTIN4 mRNA expression in TCGA (p=0.11), Sjödahl 2012 (p=0.6), and Seiler 2017 (p=0.06) cohorts.
Table S2 from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

Supplementary Table 2. Biodistribution data of [124I]PN67 in non-tumor bearing BALB/c mice at 2h time point post injection. Data is represented as average %ID/g {plus minus} SD with n=5 animals/group.
Table S3 from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
Authors: Tong Kit I. , Yoon Sharon , Isaev Keren , Bakhtiari Mehran , Lackraj Tracy , He Michael Y. , Joynt Jesse , Silva Anjali , Xu Maria C. , Privé Gilbert G. , He Housheng Hansen , Tiedemann Rodger E. , Chavez Elizabeth A. , Chong Lauren C. , Boyle Merrill , Scott David W. , Steidl Christian , Kridel Robert
Published: April 2023

Pathway analysis of RNA-seq results (Gene Ontology, Reactome and WikiPathways).
Figure S2 from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

Supplementary Figure 2. (A) Representative bioluminescent images (left panels) and PET images (right panels) of mice bearing 4T1-Luc tumor. The bioluminescent image was taken 1h prior to PET experiment, whereas PET images at 2 h post injection was shown. Blocking was carried out by co-injecting of 1 at 30mg/kg with the tracer. (B) PET quantitation of [124I]-PN67 uptake in 4T1-Luc tumors vs. blocking condition (1, 30 mg/kg). Muscle uptake was quantified to gauge the level of background signal. Data are average %ID/g {plus minus} SD (n = 4). %ID/g = percentage injected dose per gram, **P < 0.01. (C) Representative autoradiography of 4T1-Luc tumors from (A).
Figure S1 from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

Supplementary Figure 1. The radiolabeling product of [124I]PN67 was confirmed by co-injecting cold compound 2 (100uM in 100ul DMSO/H2O/MeCN) with the radioactive fraction (50uCi in 100ul H2O/MeCN) onto HPLC. (A) UV 235/254nm wavelength channels were used to detect absorption of cold PN67. Retention time (RT): 8.17min; (B) The radioactivity was detected by a bioscan flow-count detector. Retention time (RT): 8.28min. Radiochemical purity (>99%) was calculated based on integration of area under curve. The bioscan peak is slightly delayed compared with UV signal because of instrument setting.
Supplementary Table S3 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Table S3 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure 1 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Authors: Sharma Priyanka , Abramson Vandana G. , O'Dea Anne , Nye Lauren , Mayer Ingrid , Pathak Harsh B. , Hoffmann Marc , Stecklein Shane R. , Elia Manana , Lewis Sharon , Scott Jecinta , De Jong Jilliann A. , Wang Yen Y. , Yoder Rachel , Schwensen Kelsey , Finke Karissa , Heldstab Jaimie , LaFaver Stephanie , Williamson Stephen K. , Phadnis Milind A. , Reed Gregory A. , Kimler Bruce F. , Khan Qamar J. , Godwin Andrew K.
Published: April 2023

Kaplan-Meier estimates of overall survival
Supplementary Figure S5 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Figure S5 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure S3 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
Authors: Asleh Karama , Tu Dongsheng , Gao Dongxia , Bramwell Vivien , Levine Mark N. , Pritchard Kathleen I. , Shepherd Lois E. , Nielsen Torsten O.
Published: April 2023

The distribution of INPP4B cytoplasmic staining among "IHC non basal/PAM50 Basal-like" cases in the combined translational study cohorts of MA.5 and MA.12 clinical trials.
Supplementary file from Development and Validation of Machine Learning–based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts
Authors: Chen Kezhong , Nie Yuntao , Park Samina , Zhang Kai , Zhang Yangming , Liu Yuan , Hui Bengang , Zhou Lixin , Wang Xun , Qi Qingyi , Li Hao , Kang Guannan , Huang Yuqing , Chen Yingtai , Liu Jiabao , Cui Jian , Li Mingru , Park In Kyu , Kang Chang Hyun , Shen Haifeng , Yang Yingshun , Guan Tian , Zhang Yaxiao , Yang Fan , Kim Young Tae , Wang Jun
Published: April 2023

Supplementary file
Table S11 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S11
Detailed genetic mutations detected in 9 paired cell free DNA samples sequenced by 1021-panel.